Table 1.
Gender [n (%)] | Male | 67 (72.0) | ||
Female | 26 (28.0) | |||
Age [years] | Median | 61 | ||
Min. | 18 | |||
Max. | 92 | |||
Underlying condition [n (%)] | ||||
Haematological malignancy | 70 (75.3) | |||
Acute leukemias | ||||
• AML | 25 (26.9) | |||
• ALL | 7 (7.5) | |||
MDS | 8 (8.6) | |||
Chronic leukemias | ||||
• CLL | 1 (1.1) | |||
• MM | 7 (7.5) | |||
Myeloproliferative diseases | ||||
• CML | 6 (6.5) | |||
• MPS | 6 (6.5) | |||
Lymphoma | ||||
• HD | 2 (2.2) | |||
• NHL | 6 (6.5) | |||
Aplastic anaemia | 2 (2.2) | |||
Allogenic stem cell transplantation [n (% of haematological malignancy)] | 41 (58.6) | |||
Solid Cancer | 20 (21.5) | |||
Lung (SCLC/NSCLC) | 7 (7.5) | |||
Intestine | 5 (5.4) | |||
Mouth | 4 (4.3) | |||
Bladder | 1 (1.1) | |||
Sarcoma | 1 (1.1) | |||
Testis | 1 (1.1) | |||
Breast | 1 (1.1) | |||
Organ transplantation | 1 (1.1) | |||
Kidney | 1 (1.1) | |||
Other | 2 (2.2) | |||
EORTC/MSG | Probable | Possible | Not categorisable | Total |
Samples [n] | 11 | 51 | 41 | 103 |
Patients [n] | 10 | 46 | 37 | 93 |
Abbreviations: AML, acute myeloma leukaemia; ALL, acute lymphatic leukaemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukaemia; MM, multiple myeloma; CML, chronic myeloid leukaemia; MPS, myeloproliferative syndromes; HD, Hodgkin’s lymphoma; NHL, non-Hodgkin lymphoma; SCLC, Small Cell Lung Cancer; NSCLC, Non-Small Cell Lung Cancer.